<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - AMIODARONE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>AMIODARONE HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of arrhythmias, particularly when other drugs are ineffective or contra-indicated (including paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, ventricular fibrillation, and tachyarrhythmias associated with Wolff-Parkinson-White syndrome) (initiated in hospital or under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg 3 times a day for 1 week, then reduced to 200 mg twice daily for a further week, followed by maintenance dose, usually 200 mg daily or the minimum dose required to control arrhythmia.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg/kg, to be given over 20&#8211;120 minutes with ECG monitoring, subsequent infusions given if necessary according to response; maximum 1.2 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Ventricular fibrillation or pulseless ventricular tachycardia refractory to defibrillation</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300 mg, dose to be considered after administration of adrenaline, dose should be given from a pre-filled syringe or diluted in 20 mL Glucose 5%, then (by intravenous injection) 150 mg if required, followed by (by intravenous infusion) 900 mg/24 hours.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Possible risk of neonatal goitre; use only if no alternative.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid in severe conduction disturbances (unless pacemaker fitted)</li>
            <li>avoid in sinus node disease (unless pacemaker fitted)</li>
            <li>iodine sensitivity</li>
            <li>sino-atrial heart block (except in cardiac arrest)</li>
            <li>sinus bradycardia (except in cardiac arrest)</li>
            <li>thyroid dysfunction</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Bradycardia, hyperthyroidism, hypothyroidism, jaundice, nausea, persistent slate grey skin discoloration, phototoxicity, pulmonary toxicity (including pneumonitis and fibrosis), raised serum transaminases (may require dose reduction or withdrawal if accompanied by acute liver disorders), reversible corneal microdeposits (sometimes with night glare), sleep disorders, taste disturbances, tremor, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Conduction disturbances, onset or worsening of arrhythmia, peripheral myopathy (usually reversible on withdrawal), peripheral neuropathy (usually reversible on withdrawal),
              </p>
              <p>
                <strong>veryRare:</strong> Alopecia, aplastic anaemia, ataxia, benign intracranial hypertension, bronchospasm (in patients with severe respiratory failure), chronic liver disease, cirrhosis, epididymo-orchitis, exfoliative dermatitis, haemolytic anaemia, headache, hypersensitivity, impaired vision due to optic neuritis or optic neuropathy (including blindness), impotence, rash, sinus arrest, thrombocytopenia, vasculitis, vertigo,
              </p>
              <p>
                <strong>notKnown:</strong> Hot flushes, hypotension, respiratory distress syndrome, sweating,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> injection-site reactions,
              </p>
              <p>
                <strong>veryRare:</strong> anaphylaxis on rapid injection,
              </p>
        
            <section class="advice">
                <h3>Corneal microdeposits</h3>
              <p>Most patients taking amiodarone develop corneal microdeposits (reversible on withdrawal of treatment); these rarely interfere with vision, but drivers may be dazzled by headlights at night. However, if vision is impaired or if optic neuritis or optic neuropathy occur, amiodarone must be stopped to prevent blindness and expert advice sought.</p>
            </section>
            <section class="advice">
                <h3>Thyroid function</h3>
              <p>Amiodarone contains iodine and can cause disorders of thyroid function; both hypothyroidism and hyperthyroidism can occur. Thyrotoxicosis may be very refractory, and amiodarone should usually be withdrawn at least temporarily to help achieve control; treatment with carbimazole may be required. Hypothyroidism can be treated with replacement therapy without withdrawing amiodarone if it is essential; careful supervision is required.</p>
            </section>
            <section class="advice">
                <h3>Hepatotoxicity</h3>
              <p>Amiodarone is also associated with hepatotoxicity and treatment should be discontinued if severe liver function abnormalities or clinical signs of liver disease develop.</p>
            </section>
            <section class="advice">
                <h3>Pulmonary toxicity</h3>
              <p>Pneumonitis should always be suspected if new or progressive shortness of breath or cough develops in a patient taking amiodarone.</p>
            </section>
            <section class="advice">
                <h3>Peripheral neuropathy</h3>
              <p>Fresh neurological symptoms should raise the possibility of peripheral neuropathy.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i> (<i>Cordarone X</i>
            <tm tmtype="reg"/>), give continuously or intermittently in Glucose 5%. Suggested initial infusion volume 250&#8239;mL given over 20&#8211;120 minutes; for repeat infusions up to 1.2&#8239;g in max. 500&#8239;mL; should not be diluted to less than 600&#8239;micrograms/mL. See cardio-pulmonary resuscitation for details of infusion in extreme emergency. Incompatible with Sodium Chloride infusion fluids; avoid equipment containing the plasticizer di-2-ethylhexphthalate (DEHP).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>For administration<i> by mouth</i>, tablets may be crushed and dispersed in water; injection solution should <b>not</b> be given orally (irritant).</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Because of the possibility of phototoxic reactions, patients should be advised to shield the skin from light during treatment and for several months after discontinuing amiodarone; a wide-spectrum sunscreen to protect against both long-wave ultraviolet and visible light should be used.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>If taking amiodarone with sofosbuvir and daclatasvir, patients and their carers should be told how to recognise signs and symptoms of bradycardia and heart block and advised to seek immediate medical attention if symptoms such as shortness of breath, light-headedness, palpitations, fainting, unusual tiredness or chest pain develop.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            conduction disturbances (in excessive dosage)
          </li>
          <li>
            elderly
          </li>
          <li>
            heart failure
          </li>
          <li>
            hypokalaemia
          </li>
          <li>
            severe bradycardia (in excessive dosage)
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intravenous use:</strong>
            moderate and transient fall in blood pressure (circulatory collapse precipitated by rapid administration or overdosage)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            severe hepatocellular toxicity
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Thyroid function tests should be performed before treatment and then every 6 months. Clinical assessment of thyroid function alone is unreliable. Thyroxine (T4) may be raised in the absence of hyperthyroidism; therefore tri-iodothyronine (T3), T4, and thyroid-stimulating hormone (thyrotrophin, TSH) should all be measured. A raised T3 and T4 with a very low or undetectable TSH concentration suggests the development of thyrotoxicosis.</p><p>Liver function tests required before treatment and then every 6 months.</p><p>Serum potassium concentration should be measured before treatment.</p><p>Chest x-ray required before treatment.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>ECG monitoring and resuscitation facilities must be available.</p><p>Monitor liver transaminases closely.</p>
            </section>
            <section class="patientParameters">
              <p>If concomitant use of amiodarone with sofosbuvir and daclatasvir cannot be avoided because other anti-arrhythmics are not tolerated or contraindicated, patients should be closely monitored, particularly during the first weeks of treatment.</p><p>Patients at high risk of bradycardia should be monitored continuously for 48 hours in an appropriate clinical setting after starting concomitant treatment.</p><p>Patients who have stopped amiodarone within the last few months and need to start sofosbuvir and daclatasvir should be monitored.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of AMIODARONE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            powder,

            <div id="PHP75035"><a href="../medicinalForm/PHP75035.html" data-target="#PHP75035" data-action="load">Tablet</a></div>
            <div id="PHP75041"><a href="../medicinalForm/PHP75041.html" data-target="#PHP75041" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
